Navigation Links
BioMed Realty Trust Reports Fourth Quarter and Full-Year 2009 Financial Results
Date:2/10/2010

span> per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from October 16, 2009 through January 15, 2010. The fourth quarter common share dividend represented a 27.3% increase over the third quarter 2009 dividend. For the full year 2009, the company declared dividends totaling $0.695 per common share and $1.84376 per Series A preferred share.

Earnings Guidance

Based on the strong results for the fourth quarter and the dilutive impact of the exchangeable notes offering in January 2010, the company has revised its initial 2010 guidance for net income per diluted share and FFO per diluted share. The company's revised guidance is set forth and reconciled below.

    
    
                                                                   2010
                                                               (Low - High)
        Projected net income per diluted share
         available to common stockholders                     $0.21 – $0.31
            Add:
          Noncontrolling interests in operating
           partnership                                            $0.01
          Real estate depreciation and amortization               $1.01
          Projected FFO per diluted share                     $1.23 – $1.33

Consistent with the initial 2010 guidance, the company's revised 2010 guidance does not include the impact of potential future financing and investment activities.

The foregoing estimates are forward-looking and reflect management's view of current and future market conditions, including certain assumptions with respect to leasing activity, rental rates, occupancy levels, financing transactions, interest rates, and the amount and timing of development and redevelopment activities. The c
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine news :

1. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
2. Biomedtex Inc. Announces A. Marc Rocca as President and CEO
3. Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?
4. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
5. BioMed Realty Trust to Report 2007 Third Quarter Results
6. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
7. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
8. BioMed Realty Trust Reports Third Quarter 2007 Financial Results
9. LA BioMed research finds simpler way to assess breast cancer risk
10. LA BioMed researchers find few emergency rooms fully equipped for pediatric patients
11. BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining ... , Senior citizens can purchase a joint life insurance ... A joint policy is cheaper, but will only pay ... Life insurance can be used to cover important funeral ... online, as the application process is simple and straightforward. ...
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... 01, 2014 Join the more than 80 ... Treatment Center’s first ever charity golf tournament to benefit Project ... eating disorders who cannot afford treatment. The tournament will be ... Eureka, Mo. , The day-long event starts with 10:30 ... and award dinner will begin at 5 p.m. and will ...
(Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... four months of hormonal therapy before and with ... by as much as eight yearsespecially the development ... with potentially aggressive prostate cancer. This neoadjuvant hormonal ... developing bone metastases avoid long-term hormonal therapy later ...
... immune cells seems to halt the cells typical job ... study by Johns Hopkins researchers suggests. The findings ... ranging from annoying bouts of hay fever to deadly ... his colleagues at the Johns Hopkins Asthma and Allergy ...
... most common cause of disability in the United States. ... continues to age, the toll of this disease will escalate. ... burden and its impact on our nations health care and ... by any form of arthritisis critical. , The National Arthritis ...
... 2008) Athanasios Zavras began receiving messages from distraught ... meds to bone death in the jaw. A number ... these drugs to postpone dental work, fearing that procedures ... when Zavras, an associate professor in the Harvard School ...
... (ACP) has received a Commonwealth Fund grant of nearly $225,000 ... The grant, part of the Commonwealth Funds Patient-Centered Primary ... in November. ACP committed matching funds late in 2007. ... goal is to put the needs of the patient first. ...
... use of opioid drugs to relieve severe pain, black ... to receive these pain-relievers in emergency rooms, according to ... for more than 150,000 pain-related visits to U.S. hospitals ... of whites received opioid drugs compared with only 23 ...
Cached Medicine News:Health News:Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years 2Health News:Protein a possible key to allergy and asthma control 2Health News:Protein a possible key to allergy and asthma control 3Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2Health News:American College of Physicians receives grant to study cost of patient-centered medical home 2Health News:Blacks, Hispanics less likely to get strong pain drugs in emergency rooms 2
(Date:10/1/2014)... 2014   Plexus Information Systems, Inc. ... Management Systems (AIMS), announced a partnership with ... owned subsidiary of Quality Systems, Inc. and a ... solutions.  Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product ...
(Date:10/1/2014)... -- NeuroCall, Inc., ("NeuroCall") announced today that it recently ... services. Dr. Ricardo Garcia-Rivera , Founder and Chief ... that our quality of service has been recognized by ... support and continuity of care to patients of our ... United States ." NeuroCall currently ...
(Date:10/1/2014)... SAN MARCOS, Texas , Oct. 1, 2014 ... that it is scaling volume production of photoactive ... solar power technologies . While offering numerous advantages ... difficulty of producing large quantities of quantum dots ... has until now kept them from commercial utilization ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... Calif., Sept. 19, 2011 Amgen (NASDAQ: ... Drug Administration (FDA) approved two new indications for Prolia® ... women at high risk for fracture receiving adjuvant aromatase ... to increase bone mass in men at high risk ...
... Sept. 19, 2011 Boston Scientific Corporation (NYSE: ... a highly deliverable and ultra-low profile 0.014 inch balloon ... procedures below the knee.  The Company has begun marketing ... markets.   Boston Scientific developed the Coyote ...
Cached Medicine Technology:FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 2FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 3FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 4FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 5FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 6FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 7FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy 8Boston Scientific Launches Coyote™ Balloon Catheter 2Boston Scientific Launches Coyote™ Balloon Catheter 3Boston Scientific Launches Coyote™ Balloon Catheter 4
... Sun Med TruFlow™ Oxygen flowmeter with a ... warranty covering calibration and manufacturing defects. A ... meet most needs. Also available with all ... power take-off and double unit configurations. Our ...
... adults, the entire series of time-tested Timeter® ... the needs of care providers and patients ... accuracy. You can see it in the ... performance, year after year. Every Timeter® Classic ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: